Start / PharmaTalkRadio / Panel hitting the reset button on direct to cns delivery

PharmaTalkRadio

Panel: Hitting the "Reset" Button on Direct-to-CNS Delivery

49 min • 4 juni 2018

The expert panel will address the scientific and business challenges and opportunities in this space. Panelists will discuss the difficult nature of providing therapies for diseases of the CNS, covering both device and chemistry-enabled technologies. They will also address questions such as: Can devices take us where chemistry has not?What advances being made in the field of chemis conjugation technologies?Why is intrathecal, intracerebroventricular and intraparenchymal delivery relevant for CNS and other therapeutic categories? Finally the panel will talk about lessons learned, particularly with regard to scientific vs. business rationale. Introduction by: PJ Anand Founder President and CEO, Lifesciences Moderator: Lisa Shafer, PhD Senior Director New Devices and Bioelectronic Technologies Teva Pharmaceuticals Panelists: Dan Abrams, MD CEO, Cerebral Therapeutics, LLC Krystof Bankiewicz, MD, PhD Director, Interventional Neuro Center UCSF Mikhail "Misha" Papisov, PhD Associate Professor Harvard Medical School and Massachusetts General Hospital Lamya Shihabuddin, PhD R&D Cluster Head Neuro Rare Diseases, Sanofi R&D This Discussion took place on Day 2 of the Partnership Opportunities in Drug Delivery (PODD) 2017 Meeting.

Senaste avsnitt

Stanford's Dr Crystal Mackall on the Evolution of and Future Directions in Cell Therapy

14 augusti | 29 min

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

12 augusti | 28 min

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

12 augusti | 28 min

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00